Cargando…

(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort

BACKGROUND: To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment. METHODS: A retrospective PMR cohort (clinical diagnosis) from a rheumatology department was used. All visits > 30 days after starting GC treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolhuis, Thomas E., Marsman, Diane, van den Hoogen, Frank H. J., Broeder, Alfons A. den, Broeder, Nathan den, van der Maas, Aatke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344672/
https://www.ncbi.nlm.nih.gov/pubmed/35915465
http://dx.doi.org/10.1186/s41927-022-00274-y
_version_ 1784761270075916288
author Bolhuis, Thomas E.
Marsman, Diane
van den Hoogen, Frank H. J.
Broeder, Alfons A. den
Broeder, Nathan den
van der Maas, Aatke
author_facet Bolhuis, Thomas E.
Marsman, Diane
van den Hoogen, Frank H. J.
Broeder, Alfons A. den
Broeder, Nathan den
van der Maas, Aatke
author_sort Bolhuis, Thomas E.
collection PubMed
description BACKGROUND: To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment. METHODS: A retrospective PMR cohort (clinical diagnosis) from a rheumatology department was used. All visits > 30 days after starting GC treatment and with > 2.5 mg/day oral prednisolone were used as potential relapse visits. Often used relapse criteria (1) rheumatologist judgement, (2) treatment intensification-based relapse) were assessed for agreement in this cohort. The proportion of patients with treatment-based relapse within 1 and 2 years of treatment and the relapse incidence rate were used to assess unadjusted associations with candidate predictors using logistic and Poisson regression respectively. After using a multiple imputation method, a multivariable model was developed and assessed to predict the occurrence (yes/no) of relapse within the first year of treatment. RESULTS: Data from 417 patients was used. Relapse occurred at 399 and 321 (of 2422) visits based on the rheumatologist judgement- and treatment-based criteria respectively, with low to moderate agreement between the two (87% (95% CI 0.86–0.88), with κ = 0.49 (95% CI 0.44–0.54)). Treatment-based relapse within the first two years was significantly associated with CRP, ESR, and pre-treatment symptom duration, and incidence rate with only CRP and ESR. A model to predict treatment intensification within the first year of treatment was developed using sex, medical history of cardiovascular disease and malignancies, pre-treatment symptom duration, ESR, and Hb, with an AUC of 0.60–0.65. CONCLUSION: PMR relapse occurs frequently, although commonly used criteria only show moderate agreement, underlining the importance of a uniform definition and criteria of a PMR specific relapse. A model to predict treatment intensification was developed using practical predictors, although its performance was modest. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00274-y.
format Online
Article
Text
id pubmed-9344672
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93446722022-08-03 (Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort Bolhuis, Thomas E. Marsman, Diane van den Hoogen, Frank H. J. Broeder, Alfons A. den Broeder, Nathan den van der Maas, Aatke BMC Rheumatol Research Article BACKGROUND: To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment. METHODS: A retrospective PMR cohort (clinical diagnosis) from a rheumatology department was used. All visits > 30 days after starting GC treatment and with > 2.5 mg/day oral prednisolone were used as potential relapse visits. Often used relapse criteria (1) rheumatologist judgement, (2) treatment intensification-based relapse) were assessed for agreement in this cohort. The proportion of patients with treatment-based relapse within 1 and 2 years of treatment and the relapse incidence rate were used to assess unadjusted associations with candidate predictors using logistic and Poisson regression respectively. After using a multiple imputation method, a multivariable model was developed and assessed to predict the occurrence (yes/no) of relapse within the first year of treatment. RESULTS: Data from 417 patients was used. Relapse occurred at 399 and 321 (of 2422) visits based on the rheumatologist judgement- and treatment-based criteria respectively, with low to moderate agreement between the two (87% (95% CI 0.86–0.88), with κ = 0.49 (95% CI 0.44–0.54)). Treatment-based relapse within the first two years was significantly associated with CRP, ESR, and pre-treatment symptom duration, and incidence rate with only CRP and ESR. A model to predict treatment intensification within the first year of treatment was developed using sex, medical history of cardiovascular disease and malignancies, pre-treatment symptom duration, ESR, and Hb, with an AUC of 0.60–0.65. CONCLUSION: PMR relapse occurs frequently, although commonly used criteria only show moderate agreement, underlining the importance of a uniform definition and criteria of a PMR specific relapse. A model to predict treatment intensification was developed using practical predictors, although its performance was modest. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s41927-022-00274-y. BioMed Central 2022-08-02 /pmc/articles/PMC9344672/ /pubmed/35915465 http://dx.doi.org/10.1186/s41927-022-00274-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Bolhuis, Thomas E.
Marsman, Diane
van den Hoogen, Frank H. J.
Broeder, Alfons A. den
Broeder, Nathan den
van der Maas, Aatke
(Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
title (Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
title_full (Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
title_fullStr (Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
title_full_unstemmed (Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
title_short (Dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
title_sort (dis)agreement of polymyalgia rheumatica relapse criteria, and prediction of relapse in a retrospective cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344672/
https://www.ncbi.nlm.nih.gov/pubmed/35915465
http://dx.doi.org/10.1186/s41927-022-00274-y
work_keys_str_mv AT bolhuisthomase disagreementofpolymyalgiarheumaticarelapsecriteriaandpredictionofrelapseinaretrospectivecohort
AT marsmandiane disagreementofpolymyalgiarheumaticarelapsecriteriaandpredictionofrelapseinaretrospectivecohort
AT vandenhoogenfrankhj disagreementofpolymyalgiarheumaticarelapsecriteriaandpredictionofrelapseinaretrospectivecohort
AT broederalfonsaden disagreementofpolymyalgiarheumaticarelapsecriteriaandpredictionofrelapseinaretrospectivecohort
AT broedernathanden disagreementofpolymyalgiarheumaticarelapsecriteriaandpredictionofrelapseinaretrospectivecohort
AT vandermaasaatke disagreementofpolymyalgiarheumaticarelapsecriteriaandpredictionofrelapseinaretrospectivecohort